Search

We assessed the outcome in 50 patients with NSCLC treated from June 1991 through June 1994 with multiagent chemotherapy (Cisplatin 100 mg/m 2 , Ifosfamide 3 g/m 2 , and Mitomicine 6 mg/m 2 , given every 21 days). We studied too, the survival and the recurrence. There were 47 males and three females, and their ages ranged from 36 to 78 years. According to the staging, 3 were in Stage I, 3 in stage II, 3 in stage IlIA, 26 in Satge IlIB, and 4 in Stage IV. The actuarial survival at 1 year for the 50 patients was 42%, with a median survival of 8 months. In the total group, 24 responded (4 CR, 20 PR), with an actuarial survival at 12 months of 68% and a median survival of 15 months; vs 12% and 6 months for patients who did not respond, respectively. Recurrence was observed in 15 patients, five In the CNS, four in the lung, three in the liver, two in bone and one supraclavicular. Conclusions Patients who responded to chemotherapy showed a significantly longer survival than non-responding. It is remarkable the high incidence of brain and local recurrence, that could justify the use of Conbination with other local treatments.